SCHEMBL9923872

SCHEMBL9923872

Cc1c(NS(=O)(=O)c2ccccc2)nc2ccccn12

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.47
TSHR P16473 1/20 0.47
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 4/20 0.46
HPGD P15428 2/20 0.46
HSD17B10 Q99714 2/20 0.46
NPSR1 Q6W5P4 3/20 0.45
MAPK1 P28482 1/20 0.45
GAA P10253 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
RXFP1 Q9HBX9 1/20 0.44
HTR6 P50406 4/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CYP19A1 P11511 1/20 0.42
CYP2C9 P11712 1/20 0.42
PKM P14618 1/20 0.42
LMNA P02545 1/20 0.42
PIK3CA P42336 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9925340 0.87 ALDH1A1 (0.41) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL9893198 0.84 ALDH1A1 (0.48) MAPTTSHRKDM4EALDH1A1HPGD
SCHEMBL9923992 0.83 HTR6 (0.46) MAPTTSHRKDM4EALDH1A1HPGD
SCHEMBL9893468 0.79 KDM4E (0.42) MAPTKDM4EALDH1A1HPGDNPSR1
SCHEMBL9893287 0.78 HSD11B1 (0.45) MAPTTSHRKDM4EALDH1A1HPGD
SCHEMBL9893348 0.76 GAA (0.56) KDM4EALDH1A1HPGDHSD17B10NPSR1
SCHEMBL9923911 0.73 KDM4E (0.47) MAPTTSHRKDM4EALDH1A1HPGD
SCHEMBL16284288 0.68 KDM4E (0.78) MAPTTSHRKDM4EALDH1A1HPGD
SCHEMBL4061727 0.68 JAK2 (0.56) MAPTTSHRKDM4EALDH1A1HPGD
SCHEMBL6298212 0.68 HTR6 (0.66) KDM4EALDH1A1HPGDHSD17B10HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067935-B2 Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2015-06-30 US disclosed
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2014-03-27 US disclosed
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 MAPT 2927/4885TSHR 1263/4885KDM4E 3480/4885
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 MAPT 2927/4885TSHR 1263/4885KDM4E 3480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.